As of 2025-01-17, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -26.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 6,960.87 mil USD. BPMC's TTM EBITDA according to its financial statements is -261.71 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 14.5x | 13.4x |
| Forward P/E multiples | 14.3x - 23.3x | 17.2x |
| Fair Price | (63.42) - (64.58) | (67.71) |
| Upside | -160.5% - -161.6% | -164.5% |
| Date | EV/EBITDA |
| 2025-01-13 | -25.91 |
| 2025-01-10 | -22.36 |
| 2025-01-08 | -23.14 |
| 2025-01-07 | -24.04 |
| 2025-01-06 | -22.87 |
| 2025-01-03 | -22.58 |
| 2025-01-02 | -22.30 |
| 2024-12-31 | -22.31 |
| 2024-12-30 | -22.21 |
| 2024-12-27 | -22.84 |
| 2024-12-26 | -23.38 |
| 2024-12-24 | -23.09 |
| 2024-12-23 | -23.06 |
| 2024-12-20 | -23.02 |
| 2024-12-19 | -22.72 |
| 2024-12-18 | -23.42 |
| 2024-12-17 | -24.56 |
| 2024-12-16 | -24.29 |
| 2024-12-13 | -23.76 |
| 2024-12-12 | -23.61 |
| 2024-12-11 | -24.07 |
| 2024-12-10 | -24.29 |
| 2024-12-09 | -24.09 |
| 2024-12-06 | -24.43 |
| 2024-12-05 | -24.22 |
| 2024-12-04 | -24.57 |
| 2024-12-03 | -24.57 |
| 2024-12-02 | -24.83 |
| 2024-11-29 | -24.53 |
| 2024-11-27 | -24.22 |
| 2024-11-26 | -24.11 |
| 2024-11-25 | -23.92 |
| 2024-11-22 | -23.99 |
| 2024-11-21 | -24.59 |
| 2024-11-20 | -24.15 |
| 2024-11-19 | -24.10 |
| 2024-11-18 | -23.03 |
| 2024-11-15 | -22.67 |
| 2024-11-14 | -24.35 |
| 2024-11-13 | -24.65 |
| 2024-11-12 | -24.59 |
| 2024-11-11 | -25.38 |
| 2024-11-08 | -25.61 |
| 2024-11-07 | -25.75 |
| 2024-11-06 | -25.32 |
| 2024-11-05 | -24.82 |
| 2024-11-04 | -23.44 |
| 2024-11-01 | -23.15 |
| 2024-10-31 | -22.38 |
| 2024-10-30 | -22.80 |